Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

  title={Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.},
  author={Lisa Bodei and Dik J. Kwekkeboom and Mark S. Kidd and Irvin Mark Modlin and Eric P. Krenning},
  journal={Seminars in nuclear medicine},
  volume={46 3},
Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades and has been accepted as an effective therapeutic modality in the treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs) or neuroendocrine tumors (NETs). The two most commonly used radiopeptides for PRRT, (90)Y-octreotide and (177)Lu-octreotate, produce disease-control rates of 68%-94%, with progression-free survival rates that compare favorably with chemotherapy… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS